Insilico Raises $35M From Aramco Venture Arm For AI Drug Discovery
Hong Kong-based Insilico secures $35 million in Series D funding led by Aramco's Prosperity7 to advance its AI-driven drug discovery and sustainable chemistry efforts.
Hong Kong-based Insilico raises $35 million in new funding to advance its AI-driven drug discovery platform during what its CEO calls a "biotech winter." This latest infusion brings the company's total Series D round to $95 million. Prosperity7, the venture capital arm of Saudi Aramco, leads the oversubscribed round, which also sees participation from a diverse group of financial and strategic investors.
Insilico uses machine learning to identify potential drug targets and develop new medications, but its partnership with Prosperity7 opens a new avenue in sustainable chemistry. This scientific field focuses on creating environmentally benign chemical products and processes, an area where Aramco invests heavily. The company operates R&D teams across Hong Kong, Shanghai, and New York, making it an ideal partner for a fund that seeks scalable global opportunities connecting China and the Middle East.
The company's cross-continental strategy mirrors the early semiconductor industry, where research happens primarily in the U.S. while production relies heavily on Chinese contract research organizations (CROs). China has emerged as a major hub for these outsourced pharmaceutical services. By bridging these two markets, Insilico leverages massive investment in Chinese CROs while maintaining its cutting-edge AI research operations in the United States.